Clinical trial
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
NCT00432237 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00432237 |
|---|---|
| Title | Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016) |
| Official title | A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK0974 in the Acute Treatment of Migraine With or Without Aura |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | MK0974 50 mg, MK0974 150 mg, MK0974 300 mg, Comparator: Placebo |
| Enrollment | 1,703 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Feb 7, 2007 |
| Last update posted | Jul 3, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: